The Role of IL-6 Signaling in Cancer-induced Bone Pain
Cancer pain is the most frequent, feared, and disruptive symptom of the disease and is a primary factor in diminished quality of life in cancer patients. Moreover, opiates, commonly used for moderate-to-severe cancer pain, are associated with debilitating side effect that further diminish the patients' quality of life. There is a need for testing and development of improved therapies for cancer-induced pain. The proposed experiments examine whether prolonged blockage of IL-6 signaling will effectively block tumor-induced cancer pain, and if alleviation of cancer-induced pain will correspond to altered disease progression.